Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Retained Earnings (2021 - 2025)

InMed Pharmaceuticals' Retained Earnings history spans 5 years, with the latest figure at -$121.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 94207.46% year-over-year to -$121.0 million; the TTM value through Dec 2025 reached -$121.0 million, down 94207.46%, while the annual FY2025 figure was $128569.0, 100.12% up from the prior year.
  • Retained Earnings reached -$121.0 million in Q4 2025 per INM's latest filing, down from -$119.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $128569.0 in Q4 2021 to a low of -$121.0 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$69.5 million, with a median of -$99.0 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.12% in 2024, then tumbled 94207.46% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $128569.0 in 2021, then changed by 0.0% to $128569.0 in 2022, then plummeted by 82079.33% to -$105.4 million in 2023, then surged by 100.12% to $128569.0 in 2024, then crashed by 94207.46% to -$121.0 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Retained Earnings are -$121.0 million (Q4 2025), -$119.0 million (Q3 2025), and $128569.0 (Q2 2025).